B2M and cancer: A recent study of patients undergoing anti-PD-1 therapy (pembrolizumab) for metastatic melanoma who experienced cancer relapse after tumor regression, found that a majority of relapsing cancer cells contained somatic mutations in genes associated with interferon receptor signaling (JAK1 and JAK2) or antigen presentation (B2M) (169).